РусскийEnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Ambrosova T., Kovalyova O., Ashcheulova T.

    THERAPEUTICAL POTENTIAL OF LOSARTAN IN HYPERTENSIVE OBESE PATIENTS


    About the author: Ambrosova T., Kovalyova O., Ashcheulova T.
    Heading CLINICAL MEDICINE
    Type of article Научная статья
    Annotation 20 patients with 2 stage AH, 1-3 obesity degree (BMI 36.25±1.01 kg/m2) were examined. Average age was 58.9±2.87 years. In the patients with AH associated with obesity significant antihyper-tensive efficacy of losartan monotherapy was found. SBP level reduced on 22.3 mm Hg, DBP – on 11.4 mmHg. Target BP levels was in 90% of patients at the end of study period. In patients with AH and concomitant obesity on the base of losartan therapy statistically significant decreasing of TNF-α activity on 22.44% and PAI -1 – on 22.54% as compared with baseline were detected.
    Tags arterial hypertension, obesity, adipokines, angiotensin II receptors antagonists
    Bibliography
    • Демографія і стан здоров’я народу України /За ред.Коваленка В.М., Корнацького В.М., 2010. -  С. 31-50.
    • Guidelines for the management of arterial hypertension. The Tack Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur.Heart.J. – 2007. – Vol.28. – P.1462-1536.
    • Ahima R. S. Adipose Tissue as an Endocrine Organ / R. S. Ahima // Obesity. –2006. – Vol.14(5). –P.242S - 249S.
    • Aksnes T.A. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors / T.A.Aksnes, H.M.Reims,  S.Guptha // J.Hum.Hypertens. -  2006. – Vol.20(11). – P. 860-866.
    • Aksnes T.A. Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity/T.A.Aksnes, I.Seljeflot, P.A.Torjesen//Metabolism.– 2007.– Vol.56(11).– P.1470-1477.
    • Bastard J.P. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss / J.P.Bastard, C.Jardel, E. Bruckert //J.Clin.Endocrinol.Metab. – 2000. – Vol.85. –P.3338 –3342.
    • Bastelica D. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits / D.Bastelica, P.Morange, B.Berthet // Arterioscler. Thromb.Vasc.Biol. –2002. – Vol.22. –P.173–178.
    • Binder B.R. Plasminogen activator inhibitor-1: physiological and pathophysiological roles / B.R.Binder, G.Christ, F.Gruber // News Physiol Sci. – 2002. – Vol.17. –P. 56-61.
    • Chow W.S. Hypoadiponectinemia as a predictor for the development of hypertension / W.S.Chow, B.Cheuhg, A.Tso // Hypertension. –2007. –Vol.49. –P.1455 –1469.
    • Festa A. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study / A.Festa, R.J.D’Agostino, R.P Tracy. // Diabetes. –2002. – Vol. 51. – P. 1131–1137.
    • Juhan-Vague I. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk / I.Juhan-Vague, M.C Alessi., A.Mavri // J.Thromb.Haemost. – 2003. – Vol.1. – P.1575–1579.
    • Koh K.K. Angiotensin II typereceptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen inhypertensive patients: a randomized, double-blind, placebo controlled study / K.K.Koh, W.J.Chung, J.Y. Ahn // Atherosclerosis. – 2004. –  Vol.177. – P.155-160.
    • Lau D. Adipokines: molecular links between obesity and atherosclerosis / D.Lau, B.Dhillon, H.Yan // Am.J.Physiol.Heart.Circ.Physiol. – 2005. – Vol.288. – P.2031-2041.
    • Li-Saw-Hee F.L. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial / F.L.Li-Saw-Hee, D.G.Beevers, G.Y.H. Lip // Int.J.Cardiol. -2001. – Vol.78. – P.241-246.
    • Mallamaci F. Adiponectin and essential hypertension / F.Mallamaci, C.Zoccali, F.Cuzzola // J. Nephrol. –2002. –Vol.15. –P. 507 –511.
    • Nakamura M. Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotorion in human resistance vessel / M.Nakamura, H.Yoshida, N. Arakawa // J.Cardiovasc.Pharmacol. – 2000. – Vol.36. – P.487–492.
    • Paterna S. Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension  / S.Paterna, V.Di Garbo, G.Avellone // Clin.Drug.Investig. – 2003. – Vol.23(11). - P.717-724.
    • Pradhan A.D. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus / A.D.Pradhan, J.E.Manson, N.Rifai // JAMA. –2001. – Vol.286. – P.327–334.
    •  Sardo M.A.Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients /M.A.Sardo, M.Castaldo, M.Cinquegrani // Angiology. – 2004. – Vol.55(2). – P.195-203.
    • Schillaci G. Hypoadiponectinemia: a novel link between obesity and hypertension / G.Schillaci, M. Pirro // Hypertension. – 2007. – Vol.49. – P.1217 – 1219.
    • Trujillo M.E. Adipose tissue-derived factors: impact on health and disease / M.E.Trujillo, P.E. Scherer // Endocr. Rev. – 2006. – Vol.27.-P.762-778.
    • Uchida T. Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome /T.Uchida, M.Shimizu,  Y.Sakai //Metabolism. – 2008. – Vol.57(9). – P.1278-85.
    Publication of the article «World of Medicine and Biology» №2(29), 2011 year, 92-96 pages, index UDK 616.12 – 008.331.1 – 056.52 – 085.225.2: 577.175.8